SJM Epic Porcine Valve Trial Signals Turnaround Of St. Jude’s Valve Business
This article was originally published in The Gray Sheet
Executive Summary
St. Jude expects the introduction of its BioCor stented porcine tissue valve in the U.S. later this year to lead a roughly 13% turnaround of the firm's replacement heart valve business in 2003
You may also be interested in...
MCRI Gets Go-Ahead To Study Reduced Anticoagulation Therapy With Valves
The Medical Carbon Research Institute has received the first investigational device exemption from FDA to study whether a mechanical heart valve can be indicated for use with reduced levels of anticoagulants
MCRI Gets Go-Ahead To Study Reduced Anticoagulation Therapy With Valves
The Medical Carbon Research Institute has received the first investigational device exemption from FDA to study whether a mechanical heart valve can be indicated for use with reduced levels of anticoagulants
St. Jude Optimistic About Symmetry Despite Slower-Than-Expected Adoption
Demand for St. Jude Medical's Symmetry anastomotic bypass graft system will continue to grow slowly for the foreseeable future, even though the device is associated with a better overall patency rate than traditional sutures, the company predicts